The Analysis Of Clinical Efficacy And Survival Rate Of NACT In AEOC

Objective: To clarify the effect of neoadjuvant chemotherapy on the efficacy and survival rate of advanced ovarian cancer,to provide patients with more suitable and optimized treatment options.Methods: A total of 155 clinical data of epithelial ovarian cancer diagnosed in FIGO stage III-IV from October 2012 to October 2015 confirmed by the Department of Pathology of Gansu Provincial Hospital were collected.127 cases that met the inclusion criteria were divided into two groups:the observation group(67 cases of NACT + IDS)and the control group(60 cases of PDS).According to the clinical characteristics of the two groups,the intraoperative and postoperative indicators and survival indicators of the two groups of patients were analyzed.Results: 1.There were no significant differences in general information of the two groups(P> 0.05).2.Intraoperative observation indicators of the two groups:?The operation time in the NACT + IDS(216.27±81.34min)was shorter than that in the PDS(272.12±74.21min);?The blood loss in the NACT + IDS(308.21±24.21ml)was reduced compared with the PDS(464.16±27.21ml;?The ascites volume in the NACT + IDS(602.10±124.21ml)was reduced compared with the PDS(2550.75±454.21ml).and the difference was statistically significant(P <0.05).3.Postoperative observation indicators in both groups:?The surgical satisfaction rate in the NACT + IDS(71.6%)was higher than that in the PDS(58.3%).?The number of postoperative complications in the NACT + IDS(8 cases)was less than that in the PDS(13 cases).?The number of hospital stays in the NACT + IDS(7 day)was less than that inthe PDS(10 day),and the difference was statistically significant(P <0.05).4.The total effective rate of the two groups:NACT + IDS was 64%,PDS was 51%.The difference between the two groups was statistically significant(P <0.05).5.Comparison of survival rates between the two groups:?The mortality of the two groups:NACT + IDS was 62%,PDS was 66%,and the difference was not statistically significant(P> 0.05).The 1-year survival rate,2-year survival rate,and 3-year survival rate were similar between the two groups,and the differences were not statistically significant(P> 0.05).?The progression-free survival and overall survival of the two groups: in the NACT + IDS(20.7 months and 46.5 months),PDS(18.2 months and 46.7months).There was a statistically significant difference in progression-free survival between the two groups of patients(P<0.05).There was no significant difference in overall survival between the two groups(P> 0.05).Conclusion: Implementing 2-3 cycles of neoadjuvant chemotherapy before surgical treatment of advanced epithelial ovarian cancer can help reduce the size of the primary tumor,decrease the amount of ascites,and the serum CA125,and the patient's intraoperative related indicators and short-term prognosis have been significantly improved.However,the patients' 1-year survival rate,3-year survival rate,5-year survival rate,and overall survival rate did not improve significantly.